Watch Ticker

Viridian Therapeutics, Inc. Common Stock

Go to Viridian Therapeutics, Inc. Common Stock Website

$17.20

-0.24 (-1.38%)

Live

Previous Close

$17.2

Day Range

$15.7 - $17.79

Previous Day Range

$16.43 - $17.56

Market Cap

$1.4 billion USD

Day Vol.

1.4 million

Previous Day Vol.

941539

Currency

USD

Primary Exchange

Nasdaq

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-00...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Jesterai - Viridian (VRDN) Q2 Net Loss Widens 55%

Viridian Therapeutics reported Q2 2025 results, highlighting progress in thyroid eye disease treatment with veligrotug, securing FDA Breakthrough Therapy Designation and a $70 million licensing deal with Kissei Pharmaceutical, while experiencing increased research expenses and net losses.

Related tickers: VRDN.

Read Full Article

Researchandmarkets.Com - Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - Global Forecast to 2030

The global ophthalmic disease therapeutics market is projected to grow significantly due to factors like the introduction of innovative treatments, rising disposable incomes, and expanding healthcare infrastructure. The market is segmented by indication, therapies, and distribution channel.

Related tickers: VRDN, VTRS, SNY, NVS, BAYRY, TEVA, RHHBY, ABBV, GSK.

Read Full Article

Trending Tickers

Please sign in to view